Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
Go back to Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients| (NASDAQ: SYRE) | Delayed: 100.32 +11.98 (13.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $88.34 | 52 Week High | $ | |||
| Open | $95.00 | 52 Week Low | $ | |||
| Day High | $101.71 | P/E | N/A | |||
| Day Low | $95.00 | EPS | $ | |||
| Volume | 2,804,586 | |||||
